Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
CONCLUSIONS: Travel burden, linked to clinic visits for G-CSF administration following myelosuppressive chemotherapy, is associated with sub-optimal use of G-CSF prophylaxis which may result in a higher incidence of FN.
PMID: 29661043 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Lymphoma | Medicare | Non-Hodgkin's Lymphoma | Ovarian Cancer | Ovaries | Research | Study